Form 4: Chimerix CEO Andriole Reports Disposal of Shares and Options Following Merger with Jazz Pharmaceuticals

Michael Andriole, President and CEO of Chimerix, reports the disposal of common stock and stock options due to the merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Summary

• Michael T. Andriole, President and CEO of Chimerix, filed a Form 4 on April 21, 2025, reporting changes in beneficial ownership of Chimerix securities.
• The filing details the disposal of 630,828 shares of common stock at $8.55 per share due to the merger with Jazz Pharmaceuticals.
• The merger, effective April 21, 2025, resulted in Chimerix becoming an indirect wholly-owned subsidiary of Jazz Pharmaceuticals.
• Andriole also reported the disposal of several employee stock options with varying exercise prices and expiration dates, which were either cashed out (for 'in the money' options) or cancelled (for options not 'in the money').
• The disposal of shares and options is pursuant to the Agreement and Plan of Merger dated March 4, 2025.
• 21,225 shares were acquired under the Issuer's Employee Stock Purchase Plan on March 10, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a clear exit strategy for shareholders with a cash payout. The cancellation of some options is a negative, but the overall transaction is a positive event for Chimerix shareholders.

Positives

• The merger provided a cash payment of $8.55 per share for Chimerix shareholders.
• Vested 'in the money' stock options were cashed out, providing additional value to option holders.

Negatives

• Unvested stock options that were not 'in the money' were cancelled with no consideration.

Risks

• The document does not explicitly mention any ongoing risks, but the merger means Chimerix is no longer an independent entity.

Future Outlook

The document does not provide a future outlook for the merged entity.

Management Comments

• The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement.
• In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

Industry Context

The acquisition of Chimerix by Jazz Pharmaceuticals reflects a trend of consolidation in the pharmaceutical industry, where larger companies acquire smaller firms with promising drug candidates or technologies.

Comparison to Industry Standards

• Mergers and acquisitions in the pharmaceutical industry are common, with deal values varying widely based on the target company's pipeline and market potential.
• Comparable deals include Gilead's acquisition of Kite Pharma and Takeda's acquisition of Shire, both aimed at expanding their respective therapeutic areas.
• The $8.55 per share offer price represents a premium over Chimerix's pre-announcement stock price, which is typical in such transactions.

Stakeholder Impact

• Shareholders received $8.55 per share in cash.
• Employees with vested 'in the money' options received a cash payment.
• Chimerix now operates as a wholly-owned subsidiary of Jazz Pharmaceuticals.

Key Dates

Keywords

Merger, Chimerix, Jazz Pharmaceuticals, Form 4, Beneficial Ownership, Stock Options, Common Stock, Andriole, CEO